If you’re working in the field of rare diseases, the World Orphan Drug Congress Geneva is the only must attend meeting. With the event still 6 weeks away, over 250 of your peers have confirmed to network, collaborate and find solutions for their orphan drug development challenges.
Also, biotech delegates with orphan drug designation for their pipeline are eligible to take advantage of a poster presentation in the main exhibition area.
With endorsement & sponsorship from leading orphan drug manufacturers, both learning and partnering opportunities will be in abundance. So if you are looking to meet industry partners, payers, national rare disease alliances and patient advocacy groups, then the World Orphan Drug Congress, Geneva will be your most valuable business trip in 2013, setting you up perfectly for growth next year.